(Last updated: September 2021)

Appendix B: Panel Roster and Financial Disclosures

Human Papillomavirus

Human Papillomavirus
Member Institution Financial Disclosure
Company Relationship
Darron Brown Indiana University, School of Medicine Pfizer

Johnson & Johnson

Novavax

Lilly
Equity Interest
PDS Biotechnologies Scientific Advisory Board
Merck Research Support (paid to institution)
Susan Cu-Uvin* Brown University, Warren Alpert Medical School United Nations Population Fund Research Support (paid to institution)
Mark Einstein Rutgers New Jersey Medical School

AstraZeneca

Inovio

Iovance

Johnson & Johnson

Pfizer

VBL Therapeutics

Research Support (paid to institution)

Aseiris

Becton-Dickinson

Douglas

Inovio

Merck

Papivax

PDS Biotechnologies

Consulting fee (paid to institution)
Lauri Markowitz Centers for Disease Control and Prevention None N/A
L. Stewart Massad Washington University in St. Luis, School of Medicine None N/A
Anna-Barbara Moscicki University of California Los Angeles, School of Medicine Merck Scientific Advisory Board
Joel Palefsky University of California, San Francisco, School of Medicine Merck Research Support (paid to institution)
Elizabeth Stier Boston University Medical Center None N/A
Howard Strickler Albert Einstein College of Medicine Arbor Vista

MTM Laboratories/Ventura-Roche

BD Diagnostics
Research Support (paid to institution)
John Weiser Centers for Disease Control and Prevention None N/A
Timothy Wilkin Weill Cornell Medicine Merck Scientific Advisory Board
Merck

ViiV Healthcare
Research Support (paid to institution)
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting is from July 2021 through July 2022.

 

Download Guidelines